DURECT CorpDRRX
About: Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
Employees: 58
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
170% more call options, than puts
Call options by funds: $254K | Put options by funds: $94K
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
2% less capital invested
Capital invested by funds: $9.71M [Q2] → $9.5M (-$209K) [Q3]
1.33% less ownership
Funds ownership: 24.25% [Q2] → 22.92% (-1.33%) [Q3]
4% less funds holding
Funds holding: 45 [Q2] → 43 (-2) [Q3]
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for DRRX.